Abstract: The present invention relates in a first aspect to a method for diagnosing tuberculosis infection calculating a score based on the expression of a predetermined set of genes and as well as diagnosing or predicting the clinical outcome of the tuberculosis infection based on said score. In another aspect, a method for treatment monitoring and determining treatment duration in an individual with tuberculosis infection is provided. Said method includes the determination of the expression level of predetermined genes, calculating a value based thereon and the therapy monitoring or treatment monitoring and determining treatment duration in said individual accordingly. Moreover, a method for determining the therapy-end of a treatment of tuberculosis infection in an individual affected with tuberculosis infection is provided.

Abstract: The present invention relates to crystalline valbenazine ditosylate, in particular to a crystalline hydrate of valbenazine ditosylate and a crystalline anhydrate of valbenazine ditosylate, and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline hydrate or the crystalline anhydrate, preferably in an effective and/or predetermined amount and to the use of said pharmaceutical composition as a medicament, in particular for the treatment of hyperkinetic movement disorders such as tardive dyskinesia.

Abstract: The invention relates to a mass-spectrometric method to determine microbial resistances to antibiotics, in which the microbes are cultured in a medium comprising an antibiotic, and a mass spectrum of the microbes is acquired after they have been cultured. The method is characterized by the fact that any microbial growth taking place during the culture is mass-spectrometrically determined with the aid of a reference substance, which is added in a dosed amount and is co-measured in the mass spectrum, wherein a growth in microbes indicates the resistance to the antibiotic.

Abstract: The present disclosure generally relates to crystalline valbenazine. The present disclosure also generally relates to a pharmaceutical composition comprising crystalline valbenazine, as well of methods of using crystalline valbenazine in the treatment of hyperkinetic disorders, and methods for obtaining such forms.

Abstract: The present invention relates to crystalline valbenazine ditosylate, in particular to a crystalline hydrate of valbenazine ditosylate and a crystalline anhydrate of valbenazine ditosylate, and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline hydrate or the crystalline anhydrate, preferably in an effective and/or predetermined amount and to the use of said pharmaceutical composition as a medicament, in particular for the treatment of hyperkinetic movement disorders such as tardive dyskinesia.

Abstract: The present invention relates to a brexpiprazole dihydrate crystalline form having a particle size distribution of d50 of at most 10 ?m and less than 5% w/w of brexpiprazole anhydrate. The present invention also relates to a process for preparing this brexpiprazole dihydrate crystalline form and to pharmaceutical compositions thereof. The present invention also relates to a process for determining the absence of brexpiprazole anhydrate in this brexpiprazole dihydrate crystalline form. This brexpiprazole dihydrate crystalline form is used for the preparation of pharmaceutical compositions having delayed release properties upon intramuscular injection.

Abstract: The invention relates to a mass spectrometric method for determining microbial resistances to antibiotics. The invention provides specific methods comprising cultivation in synthetic media, in which several amino acids, preferably only a single amino acid, are isotopically labeled by incorporating 13C, 15N, 18O or 34S. If several amino acids are isotopically labeled, they are labeled in such a way that they are each heavier than the corresponding unlabeled amino acids by the same integer mass difference ?m. This ensures that the mass shifts of the peaks always amount to an integer multiple of the mass difference ?m. The total mass difference can be kept relatively small by selecting suitable amino acids. A mass shift of the protein peaks in media with antibiotics indicates that the microbes are resistant. A second embodiment first produces isotopically labeled microbes, which are then tested for their resistance by cultivating them in normal media.

Abstract: The present disclosure generally relates to crystalline valbenazine. The present disclosure also generally relates to a pharmaceutical composition comprising crystalline valbenazine, as well of methods of using crystalline valbenazine in the treatment of hyperkinetic disorders, and methods for obtaining such forms.

Abstract: A lifting device of an industrial truck includes a load handling arrangement that is raised and lowered on a lifting frame and a hydraulic lift cylinder device that is actuated by an electrically actuatable control valve device, in which an electronic control device is provided to actuate the control valve device. The electronic control device has an automated set-down mode actuated during a lowering of the load handling arrangement. The load is lowered at a lowering speed specified by a deflection of a control element to the designated surface. As the control element continues to be deflected into the lowering position, the lowering of the load handling arrangement is terminated by the electronic control device by actuating the control valve device into a shut-off position to prevent the load handling arrangement from being set down on the designated surface.

Abstract: The present invention relates to non-stoichiometric crystalline hydrates of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, processes for their preparation, and their use as medicaments. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel crystalline hydrates.

Abstract: The present invention relates to a brexpiprazole dihydrate crystalline form having a particle size distribution of d50 of at most 10 ?m and less than 5% w/w of brexpiprazole anhydrate. The present invention also relates to a process for preparing this brexpiprazole dihydrate crystalline form and to pharmaceutical compositions thereof. The present invention also relates to a process for determining the absence of brexpiprazole anhydrate in this brexpiprazole dihydrate crystalline form. This brexpiprazole dihydrate crystalline form is used for the preparation of pharmaceutical compositions having delayed release properties upon intramuscular injection.

Abstract: A method for wireless data transmission between a first communication device and a second communication device, wherein the first communication device acts as a data source and the second communication device acts as a data sink, includes: splitting, by the data source, data to be transmitted from the data source to the data sink into a carrier signal for a radio channel and an optical carrier signal by modulating the carrier signals; transmitting the data via a hybrid transmission path from the data source to the data sink by simultaneously transmitting some of the data via the radio channel and some of the data via a wireless optical direct channel; and merging, by the data sink, via a demodulation process, the data transmitted via the radio channel and the data transmitted via the wireless optical direct channel.

Abstract: The invention relates to a mass-spectrometric method to determine microbial resistances to antibiotics, in which the microbes are cultured in a medium comprising an antibiotic, and a mass spectrum of the microbes is acquired after they have been cultured. The method is characterized by the fact that any microbial growth taking place during the culture is mass-spectrometrically determined with the aid of a reference substance, which is added in a dosed amount and is co-measured in the mass spectrum, wherein a growth in microbes indicates the resistance to the antibiotic.

Abstract: The invention relates to a mass-spectrometric method to determine microbial resistances to antibiotics, in which the microbes are cultured in a medium comprising an antibiotic, and a mass spectrum of the microbes is acquired after they have been cultured. The method is characterized by the fact that any microbial growth taking place during the culture is mass-spectrometrically determined with the aid of a reference substance, which is added in a dosed amount and is co-measured in the mass spectrum, wherein a growth in microbes indicates the resistance to the antibiotic.

Abstract: A method for wireless data transmission between a first communication device and a second communication device, wherein the first communication device acts as a data source and the second communication device acts as a data sink, includes: splitting, by the data source, data to be transmitted from the data source to the data sink into a carrier signal for a radio channel and an optical carrier signal by modulating the carrier signals; transmitting the data via a hybrid transmission path from the data source to the data sink by simultaneously transmitting some of the data via the radio channel and some of the data via a wireless optical direct channel; and merging, by the data sink, via a demodulation process, the data transmitted via the radio channel and the data transmitted via the wireless optical direct channel.

Abstract: A method of dynamically allocating network resources in an access network and a customer network includes: determining, by a control unit, positions of all users of the customer network; bringing, by the control unit, the customer network and/or a component of the customer network into a first predefined state, based on determining that no user of the customer network is checked in to the customer network; and reallocating, by the control unit, an access port of an access multiplexer assigned to the customer network to an access network resource pool, based on determining that no user of the customer network is checked in to the customer network.

Abstract: A coupling arrangement between a fluid reservoir and a main brake cylinder for a motor vehicle brake system includes two coupling arms with one coupling aperture each on one of the fluid reservoir or main brake cylinder. The other of the fluid reservoir or main brake cylinder has a mounting portion with a receiving aperture. The coupling apertures and the receiving aperture are aligned with each other along a common axis and accept a coupling bolt. The coupling bolt is configured with a cylindrical shank portion and at least one radially protruding detent projection. At least one of the coupling arms includes a support portion, which has a support surface that radially supports the cylindrical shank portion. Part of the support portion is configured to be elastically deformable with the detent projection to produce a detent connection. The remaining part of the support portion is configured to be substantially deformation-resistant.

Abstract: A lifting device of an industrial truck includes a load handling arrangement that is raised and lowered on a lifting frame and a hydraulic lift cylinder device that is actuated by an electrically actuatable control valve device, in which an electronic control device is provided to actuate the control valve device. The electronic control device has an automated set-down mode actuated during a lowering of the load handling arrangement. The load is lowered at a lowering speed specified by a deflection of a control element to the designated surface. As the control element continues to be deflected into the lowering position, the lowering of the load handling arrangement is terminated by the electronic control device by actuating the control valve device into a shut-off position to prevent the load handling arrangement from being set down on the designated surface.

Abstract: The present invention relates to novel crystalline forms of ceftaroline fosamil and to methods for their preparation. Furthermore the present invention relates to the use of the novel forms of ceftaroline fosamil for the preparation of an antibiotic medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel forms of ceftaroline fosamil and to methods of preparing the same. Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel forms of ceftaroline fosamil and ?-lactamase inhibitors.

Abstract: Genetic data may be compressed efficiently by selecting for each bi-allelic marker, from among multiple compression algorithms with different associated storage requirements that depend on the minor allele frequency of the respective marker, the algorithm that has the lowest storage requirements. Efficient approaches compress, store, and load pedigree file data. A hybrid method is used that selects between multiple alternative compression algorithms whose performance depends on the frequency of certain observable genetic variations. The hybrid method may achieve higher compression ratios than PLINK or PBAT. Further, it results in a compressed data format that, generally, does not require any overhead memory space and CPU time for decompression, and, consequently, has shorter loading times for compressed files than the binary format in PLINK or PBAT.